Described herein are compositions and methods for inducing retinal regeneration in a subject. Also described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of, and/or slowing the progression of a retinal degenerative disease, retinal damage, or retinal blindness in a subject. In some embodiments, the compositions and methods may comprise a pharmaceutical composition comprising a Foxp gene expression vector comprising a polynucleotide sequence encoding a Foxp polypeptide, functional variant thereof, or fragment thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A porous membrane can include a first plurality of near-field electrospun fibers that are substantially parallel one to another. A second plurality of near-field electrospun fibers can be deposited over the first plurality of fibers. The second plurality of fibers can also be substantially parallel one to another. The second plurality of fibers can be transverse to the first plurality of fibers, such that the second plurality of fibers cross the first plurality of fibers to form pores between adjacent fibers of the first plurality of fibers and adjacent fibers of the second plurality of fibers.
D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
D01D 5/00 - Formation of filaments, threads, or the like
D04H 1/4374 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece using different kinds of webs, e.g. by layering webs
D04H 1/559 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by welding together the fibres, e.g. by partially melting or dissolving the fibres being within layered webs
D04H 1/74 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being orientated, e.g. in parallel
3.
SYSTEMS AND METHODS FOR POINT-OF-CARE ELECTROCHEMICAL DETECTION OF BIOMARKERS IN LIQUIDS
Electrochemical detection systems and methods employ square wave voltammetry (SWV) to analyze biomarker interactions with an engineered electroactive solution containing transition metal ions, e.g., Cu2+ or Co2+. The system is designed to detect clinically relevant volatile organic biomarkers and compounds (VOBs and VOCs) linked to infections, e.g., methyl nicotinate for tuberculosis, and other respiratory or metabolic conditions. Exhaled breath from a patient is passively collected on a substrate of a mask over a predefined wear period. Any VOCs are collected as part of this breath sample as well. A defined region including the patient sample is then excised and transferred to an electrochemical cell containing an engineered electroactive solution for SWV analysis. The VOCs undergo redox reactions, generating electrochemical signatures that serve as fingerprints for disease-specific biomarkers and enable in-the-field diagnoses. The methodology is adaptable for point-of-care diagnostics, offering a rapid, portable, and low-cost alternative to conventional gas chromatography-mass spectrometry.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
4.
SYSTEMS FOR PROVIDING ADAPTIVE AND SUPPORTIVE CLOTHING
A wearable garment is provided with an integrated supporting strap structure. This strap structure includes an upper structure encircling a patient's torso and a lower structure encircling both legs of the patient and supporting the patient's torso. Each structure includes a strap extending from a first end to a second end, with connectors reversibly connecting the ends to form continuous loops. An attachment portion is integrated with the supporting structure. In use, the patient slides their legs into the lower structure and wraps the upper structure around them, securing the garment in place via the connectors. When the patient is suspended via the attachment portion, e.g., for transfer via an overhead hoist or crane, the lower structure pulls upward, gently encouraging the patient into a seated position and evenly distributing the patient's weight. When the patient is lowered, slack allows them to lay down without bunching or resistance.
A41D 13/00 - Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
A62B 35/00 - Safety belts or body harnessesSimilar equipment for limiting displacement of the human body, especially in case of sudden changes of motion
Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a medical condition related to cardiac arrhythmia syndromes in a subject using GJA1-20k as a therapeutic agent. In one embodiment, the compositions and methods comprise a GJA1-20k peptide therapy. In another embodiment, the compositions and methods comprise a GJA1-20k gene therapy.
Split enzyme reporter systems are disclosed for detecting an analyte in a mixture. Fragments of the split enzyme may be covalently bound to targeting domains that bind to target regions of an analyte, thereby causing formation of an active complex. Some split enzyme reporter systems can be used to detect an analyte without the use of analyte immobilization, blocking, or wash steps. Some reporter systems also enable rapid detection of the analyte of interest.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
C12Q 1/6804 - Nucleic acid analysis using immunogens
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
7.
SUPER-RESOLUTION IMAGING SYSTEMS AND METHODS INCLUDING EVENT-BASED IMAGING SENSORS
A super-resolution imaging method (400) can include using an event-based imaging sensor (410) having one or more pixels to receive light originating from a first portion of a scene within a focused spot. At least one of the event-based imaging sensor and the scene can be moved (420) relative to one another so that a different second portion of the scene is in the focused spot. The event-based imaging sensor can be used to detect a change in light intensity (430) caused by a feature of the first portion moving out of the focused spot or by a feature of the second portion moving into the focused spot. The feature can have a dimension smaller than the focused spot. A characteristic of the feature can be estimated (440) based on the change in light intensity and motion of the scene relative to the focused spot. A super-resolution image showing the feature can then be generated (450).
G06T 3/4053 - Scaling of whole images or parts thereof, e.g. expanding or contracting based on super-resolution, i.e. the output image resolution being higher than the sensor resolution
G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
G06T 3/4069 - Scaling of whole images or parts thereof, e.g. expanding or contracting based on super-resolution, i.e. the output image resolution being higher than the sensor resolution by subpixel displacements
H04N 25/48 - Increasing resolution by shifting the sensor relative to the scene
8.
EFFICACY MARKER IDENTIFICATION FOR CARTILAGE DONOR CELL SELECTION
A method of forming a membrane includes forming a membrane structure that includes a material comprising a polymer, a crosslinking agent, and a solvent. The membrane structure is equilibrated at a selected relative humidity for a predefined duration of time for forming hydrophilic domains in the material. The hydrophilic domains have a predefined average radius. The equilibrated membrane structure is cured to crosslink the material to at least a predefined extent.
B01J 41/07 - Processes using organic exchangers in the weakly basic form
B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
B33Y 80/00 - Products made by additive manufacturing
C08G 65/48 - Polymers modified by chemical after-treatment
C25B 13/08 - DiaphragmsSpacing elements characterised by the material based on organic materials
H01M 6/18 - Cells with non-aqueous electrolyte with solid electrolyte
H01M 8/1025 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having only carbon and oxygen, e.g. polyethers, sulfonated polyetheretherketones [S-PEEK], sulfonated polysaccharides, sulfonated celluloses or sulfonated polyesters
H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
Disclosed herein are anti-PD-1 antibodies useful in treating autoimmune diseases, treating cancer, treating metastatic cancer or preventing cancer metastasis in a subject. Further disclosed herein are anti-PD1 antibodies useful in depleting PD-1 positive cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Systems and methods for applying therapeutic ultrasound to the brain to compensate for the attenuation and dephasing of ultrasound by each individual's head. The compensation is based on relative ultrasound through-transmit measurements, which are performed using a set of ultrasonic emitters over one side of the head and a set of receivers on the other side. The measurements are performed with the head absent and present. Based on the difference between these measurements, the set of ultrasound waves is adjusted to compensate for attenuations and dephasing caused by the ultrasound wave passing into the head through the scalp and skull. The adjusted set of ultrasound waves provides intended, deterministic ultrasound intensity at the target location. The deterministic delivery enables safe and effective ultrasonic neuromodulation, local drug release from nanoparticle carriers, and microbubble-based disruption of blood-brain barrier for the delivery of drugs, genes, and stem cells across the blood-brain barrier.
ABSTRACT Systems and methods for treating neurological disorders, such as epilepsy, where a drug delivery device is implanted adjacent to a micro-region within the brain for local administration of a drug thereto, where local administration of the drug into the micro-region is effective to treat the neurological disorder while substantially avoiding adverse side effects.
A computer system is configured to remove motion artifacts in medical images using a generative adversarial network (GAN). The computer system instantiates the GAN having one or more generative network(s) and one or more discriminative network(s) that are pitted against each other to train a generative model and a discriminative model. The training uses a training dataset including a plurality of medical images that are previously classified as without significant motion artifacts for diagnostic purposes. The discriminative model is trained to classify medical images as real or artificial. The generative model is trained to enhance the quality of a medical image and remove motion artifacts by producing a medical image directly from a post-contrast image, without using a pre-contrast mask.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
G06V 10/32 - Normalisation of the pattern dimensions
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
The present disclosure is concerned with peptides comprising alanine residues and glycosylated residues (e.g., glycosylated hydroxypropline residues, a combination of glycosylated hydroxyproline residues and glycosylated threonine residues) in a particular ratio (e g., from about 3:2 to about 4:1), wherein the peptide has a minumum chain length, such as, for example a chain length of at least 30 ammo acid residues. The disclosed peptides beneficially inhibit ice crystal formation, and, therefore, offer utility in a wide range of applications, including, but not limited to biomedical cry opreservation, food technology, agriculture, cosmetics, and building materials. Thus, the disclosed peptides can be formulated into a composition (e.g., a cryoprotectant composition, an agricultural formulation, a cosmetic composition) or a food product, or, alternatively, can be attached or coated onto a surface for use in structural applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The present invention relates to novel somatostatin 4 (SST4) selective agonists as non-opioid analgesics. In particular, the present invention relates to peptides having strong SST4-selectivity for use in treatment of pain or inflammation.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
Atmospheric water harvesting systems, including an adsorbent heat exchanger that includes an adsorber structure. The adsorber structure comprises, in some embodiments, an array of fins coupled to one or more heat pipes, where an adsorbent material is included on the fins. In some embodiments, the system passes ambient air across the adsorber structure to adsorb water, then apples heat to the adsorber structure via a heat source and heat block coupled to the heat pipes to desorb the water. The desorbed water is passed through a condenser to capture the liquid water.
123456789101112131414 is each independently H or D, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the acetylated amino acid are also described.
C12P 25/00 - Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Methods of treating neurodevelopmental disorders by administering an acetylated amino acid having a carbon-nitrogen bond and acetyl group covalently bound to the nitrogen of the carbon-nitrogen bond and having a three-dimensional structure that allows the acetylated amino acid to enter cells and neurons are described. In one embodiment, the acetylated amino acid is a compound of Formula (I):
14 is each independently H or D, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the acetylated amino acid are also described.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
Bacteroides uniformis or Blautia spBacteroides uniformis or Blautia sp, and methods of treating gastrointestinal distress, inflammatory bowel disease, as well as preventing weight loss or maintain weight or increasing colon length by administering the compositions to a subject.
University of Florida Research Foundation, Inc. (USA)
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Vetter, Monica
Bosco, Alejandra
Rohrer, Baerbel
Tomlinson, Stephen
Hauswirth, William W.
Abstract
Recombinant vectors operably encoding a CR2-FH fusion protein comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising the recombinant vector, are described. Also provided are methods of using the compositions for treatment eye diseases such as macular degeneration or glaucoma.
Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are nucleic acid sequences capable of encoding a CAR polypeptide comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Also disclosed are vectors and cells comprising one or both of the CAR polypeptides and nucleic acid sequences capable of encoding CAR polypeptides. Also disclosed are methods of treating.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Described are methods for detecting an analyte in a liquid sample using negligible depletion and a fluorophore adhered to a solid phase extraction membrane.
A heart valve including a housing and a conductive mesh structure coupled to the housing. The conductive mesh structure includes a plurality of conductive tines that move between a collapsed position and a deployed position and the plurality of conductive tines electrically connect atrial tissue and ventricular tissue of a patient in the deployed position. The heart valve also includes a conduction controller positioned in the housing and electrically connected to the conductive mesh structure. The conduction controller receives a first conduction signal of the atrial tissue via the plurality of conductive tines, transmits a second conduction signal to the ventricular tissue via the plurality of conductive tines, and controls an electrical conduction pathway of the patient based on the second conduction signal.
A61N 1/368 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential comprising more than one electrode co-operating with different heart regions
A soil carbon measurement device (100) can include a subsurface support (110) configured to be inserted at least partially under a soil surface. The subsurface support can include an interior volume (114) and a. gas-permeable barrier separating the interior volume (114) from soil under the soil surface. The device (100) can also include an ultraviolet light source (1.30) positioned to expose the soil under the soil surface to ultraviolet light, and a carbon dioxide sensor (150) configured to measure a concentration of carbon dioxide in the interior volume (114) of the subsurface support (110).
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
Disclosed herein, are synergistic compositions comprising a nitroimidazole compound, a nitrofuran compound, or an anti-tumor agent; and a low minimum inhibitory concentration antibiotic, and methods of treating, preventing or inhibiting a facultative anaerobe infection by administering the compositions to a subject.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
This disclosure relates to magnetic robot devices capable of active and multidirectional transportation within a target environment such as the gastrointestinal tract. The robot device comprises a compartment configured to house one or more payload components and one or more feet joined to the compartment. At least one foot is joined to the compartment by way of a flexible connection, and the at least one foot includes a permanent magnet. The at least one foot is configured to bend relative to the compartment when exposed to a magnetic field to thereby assist in locomotion of the robot device. The compartment beneficially enables functional integration of additional components (e.g., drug and/or electronics payloads) with the robot device without disrupting effective locomotion.
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
Disclosed herein, are peptides comprising from N terminus to C terminus, a) a peptide of interest, wherein the peptide of interest having 6 to 20 amino acid residues and a C -terminal residue that facilitates cyclization; b) a G macrocyclase recognition site; c) a linker; and d) G macrocyclase; wherein the peptide is linear, wherein the peptide of interest is covalently bonded to the G macrocyclase recognition site, wherein the G macrocyclase recognition site is bond to the linker, and wherein the linker is bonded to the G macrocyclase, and methods of making cyclized peptides and generating libraries of cyclized peptides.
A method of preparing and/or delivering an osteochondral plug may include, positioning a tissue graft on a cutting guide, wherein the tissue graft may have been removed from a larger body of tissue to define a shaped surface. The tissue graft may include a top surface having a cartilage surface. The method may further include advancing a first cutter along a cutting direction toward the tissue graft to cut the tissue graft to form the osteochondral plug having an external wall parallel to the cutting direction and transverse to the top surface. Positioning the tissue graft on the cutting guide may include placing the shaped surface on a registration surface of the cutting guide. The registration surface may have a reference shape that corresponds to a shape of at least part of the shaped surface.
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (USA)
UNIVERSITY OF UTAH RESEARCH FOUNDATION (USA)
Inventor
Flanigan, Kevin
Bradbury, Allison Marie
Bonkowsky, Joshua
Pyne, Nettie Kate
Herstine, Jessica
Abstract
Provided are gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of mutations in the Eukaryotic Translation Initiation Factor 2B Subunit Epsilon (EIF2B5) gene. The EIF2B5 gene provides instructions for making one of five subunits of the elF2B protein, specifically the epsilon subunit of this protein. Such mutations are associated with a disease or disorder such as a leukoencephalopathy, a megalencephalic leukoencephalopathy, a leukodystrophy, a stroke, a migraine, epilepsy, multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), astrogliosis in aging, Huntington's Disease (HD), amyotrophic lateral sclerosis (ALS), Alexander disease, hepatic encephalopathy (HE), AicardinGoutieres syndrome, CLC-2-related disease, oculodentodigital dysplasia, and/or giant axonal neuropathy. Such leukoencephalopathies or leukodystrophies include, but are not limited to, Vanishing White Matter Disease (VWM). The disclosed gene therapy vectors provide a EIF2B5 cDNA to a subject in need which results in expression of a wild type or functional EIF2B5 protein. Also provided is a new promoter, designated gfa1405, which was designed to target astrocytes and neurons. Thus, compositions, nanoparticles, extracellular vesicles, exosomes, or vector comprising the gfa1405 promoter and methods of its use are also provided.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed embodiments relate to ensemble wireless signal classification and systems and devices the incorporate the same. Some embodiments of ensemble wireless signal classification may include energy-based classification processes and machine learning-based classification processes. In some embodiments, incremental machine learning techniques may be incorporated to add new machine learning-based classifiers to a system or update existing machine learning-based classifiers.
Disclosed are methods of determining methylation status of a target nucleic acid sequence in a sample comprising determining quantitative methylation data at two or more predetermined methylation sites in the target nucleic acid sequence, wherein the target nucleic acid sequence comprises an O6-methylguanine-DNA-methyltransferase (MGMT) promoter. Disclosed are methods of treating a subject having cancer comprising determining, from a sample, quantitative methylation data at two or more predetermined methylation sites in a MGMT promoter, wherein the sample is from the subject having cancer; and treating the subject for cancer when the quantitative methylation data at two or more predetermined methylation sites is at or above a threshold.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
32.
CORROSION PROCESSING FOR ENHANCED BIOSENSING ON MG ALLOYS
A sensor can include a functional surface that includes a magnesium alloy. The function surface can have a fluorescence enhancing microstructure formed by electrochemical corrosion of the magnesium alloy at the functional surface. A method of forming the sensor can include providing a precursor substrate having a magnesium alloy surface, and electrochemically treating the magnesium alloy surface in the presence of an electrolyte to electrochemically corrode the surface.
Asymmetric depth filtration for isolation of EVs or other desired nanoparticles from a biological or other fluid with high yield and purity in a simple, cost-effective manner. Such a method includes passing the biological fluid through the asymmetric depth filter (e.g., in a single pass) where the fluid is introduced into the filter at an entry portion, where components of the biological fluid pass through the wider entry portion of the pores before advancing towards the narrower exit portion of the pores, wherein EVs in the fluid become reversibly entrapped within the wider portion of the pores, while similarly sized soft, low-density lipids and/or proteins are pushed more deeply into the filter, so that the reversibly entrapped EVs can be released by simply reversing the flow, while the similarly sized soft low-density lipids and/or proteins remain permanently entrapped within the pores of the filter.
Disclosed herein are modified phagocytes comprising chimeric antigen receptors (CARs). Also disclosed herein are methods of treating cancer using the modified phagocytes and methods of making the modified phagocytes.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
An example method to form a fracture system includes generating a back flow or at least a lower pressure in a first well at a first zone. The back flow includes flowing a material from the first zone towards an outlet of the first zone and the lower pressure includes actively decreasing the pressure in the first zone. It is noted that the back flow may cause the first zone to exhibit the lower pressure (i.e., the back flow causes the first zone to exhibit a lower pressure than if there was no back flow). The method also includes hydraulically stimulating a second well at a second zone. Hydraulically stimulating the second well may form a fracture network between the first zone and the second zone.
In one aspect, disclosed herein are new hybridization probes that contain fluorinated carbon tags (F), methods of making these hybridization probes, and methods for using these hybridization probes for affinity capture of the probes both in purification during production and in the enrichment process using fluorous substrates. In certain embodiments, the hybridization probe comprises a) a polynucleotide having a 3′ end and a 5′ end and comprising about 20 to about 200 nucleotide units and b) one or more fluorinated affinity tags, wherein each affinity tag comprises one or more polyfluorinated carbon chains each comprising 3-30 carbon atoms; wherein the polynucleotide comprises a sequence complementary or substantially complementary to a target sequence within a target nucleic acid.
Processing flows and related systems and methods are disclosed. A computing system includes one or more data interfaces, one or more other components, and a controller. The one or more data interfaces are configured to provide an interface to a data source. The one or more other components include one or more controller plugins, one or more processing nodes, or both the one or more controller plugins and the one or more processing nodes. The controller is configured to manage interactions between the one or more data interfaces and the one or more other components and enable a user to chain together the one or more data interfaces and the one or more other components according to one or more flows. The one or more controller plugins are configured to provide results of the one or more flows to one of a user interface and a system interface.
A method and system that substantially sharpens the depth of focus. The method includes selecting a group of frequencies where the group of frequencies include a plurality of unique frequencies, assigning one of the frequencies in the group of frequencies to two or more of a plurality of transducers, driving the plurality of transducers to generate a plurality of beamlets where each beamlet includes a wave, and emitting the plurality of beamlets toward the target thereby generating an ultrasound field with reduced focal volume. The improvement in the focal volume using this method can comprise a factor of 10 or more, depending on the frequency bandwidth available to the system. The method, which can be applied for diagnostic and therapeutic applications, is entirely non-invasive and does not require labeling or a modification of elements or objects within the target space.
A thermopneumatic interface includes one or more pneumatic inlet ports in fluid communication with one or more pneumatic outlet ports and a cooling loop extending through the thermopneumatic interface. The cooling loop is configured to maintain the thermopneumatic interface at a baseline temperature. The one or more pneumatic outlet ports are configured to contact a surface of a microfluidic chip. Each pneumatic inlet port is configured to receive a change in pressure and provide the change in pressure to a corresponding pneumatic outlet port. The thermopneumatic interface is configured to maintain the microfluidic chip at the baseline temperature.
F28F 3/04 - Elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with recesses, with corrugations the means being integral with the element
Disclosed herein is a robotic ankle foot prosthesis that replicates the key biomechanical functions of the biological ankle and toe joints while matching the weight, size, and battery life of passive microprocessor-controlled prostheses. A single actuator powers the ankle and toe joints. The mechanism maximizes the mechanical energy regeneration during walking while imitating the physiological features of energy injection by way of the ankle joint and energy dissipation by way of the toe joint.
The present disclosure is concerned with methods of chemically modifying a compound to install a thioether linkage, the method comprising reacting the compound with PapB. Also disclosed are thioether compounds produced by such methods that may be useful in, for example, peptide therapeutic uses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The present disclosure is concerned with methods of generating interpeptide and intrapeptide thioether linkages and peptides made by such methods. Also disclosed are modified insulin analogs comprising intra- and/or interpeptide thioether linkages. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Described herein are medical film materials that incorporate one or more neuro-regenerative drugs into a polymer film. The polymer film includes a copolymer of lactide and caprolactone. The neuro-regenerative drug includes the macrolactam immunosuppressant FK506. The film is configured such that when placed under physiological conditions, the neuro-regenerative drug is released in an extended, substantially linear fashion for a period of at least 30 days.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A dynamic compression implant may be insertable into a bone, and may have a distal member with distal bone-engaging threads, a proximal member that slidably engages the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member distally away from the proximal member, the tension member elongates and urges the distal member to move proximally toward the proximal member. The bone screw may further have an interpositional member, formed separately from the proximal member and the distal member, that cooperates with the proximal member and the distal member to form a torque transmission feature that transmits torque between the proximal member and the distal member. The dynamic compression implant may be a bone screw, intramedullary implant, or other implant that applies compression across two bone portions.
Examples provide a system for designing a microfluidic device. The system includes an electronic processor configured to receive a set of design inputs defining hardware and operational requirements of a microfluidic device to be designed. Based on the set of design inputs, the electronic processor generates a microfluidic device design by generating an abstracted design of the microfluidic device that includes a machine-readable list of connections and a sequence of liquid processing steps to be performed by the microfluidic device, and, based on the abstracted design, generating a layout of the microfluidic device to determine placement and routing of microfluidic device components and connections between components. The electronic processor performs a simulation of the microfluidic device design, wherein results of the simulation indicate an output chemical concentration, an output flow rate, an output pressure, and/or an output temperature in the microfluidic device design.
G06T 19/00 - Manipulating 3D models or images for computer graphics
G05B 13/00 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion
The present disclosure relates to systems and methods for variant detection in Next-Generation Sequencing (NGS) data. The systems and methods detect small variants in NGS data. The systems and methods use a variation detection model to predict two haplotypes present in the sample.
A magnetic cogging parallel-elastic actuator (100) can include a motor (102) having an output shaft (104). The actuator (100) can further include a cogging-torque element (106). The cogging-torque element (106) can include a stator that is stationary relative to the motor (102) and a rotor that is rotatable relative to the stator and comprises an output shaft (104). A plurality of stator magnet elements can be disposed radially about the stator and a plurality of rotor magnet elements can be radially positioned about the rotor. The output shaft (108) of the rotor of the cogging-torque element (106) can be connected in parallel with the output shaft (104) of the motor (102) such that an output torque of the actuator (100) is a sum of a torque of the cogging-torque element (106) and a torque of the motor (102).
Disclosed are prosthetic systems comprising a powered knee upper leg prosthesis and a volitional controller configured to provide control of the prosthesis to the user. The prosthetic system may be configured to enable a user to climb a set of stairs. The prosthetic system may be activated by the activation of an EMG signal source, such as the biceps femoris muscle of the upper leg. The volitional controller of the prosthetic system may be further configured to receive a ground state signal and/or an IMU signal to determine a target knee torque for operating the powered knee of the prosthesis.
A method of producing a neodymium metal can include mixing a dissolution agent comprising magnesium with a neodymium-containing feedstock. The dissolution agent and the neodymium-containing feedstock can be heated to an elevated temperature above a melting temperature of the dissolution agent to form a neodymium-magnesium alloy. The neodymium-magnesium alloy can be exposed to hydrogen gas to convert neodymium in the alloy to a neodymium hydride. The neodymium hydride can be separated from the magnesium in the alloy. The neodymium can be optionally dehydrogenated to yield a purified neodymium product.
A method of modifying a microstructure of a titanium material can include providing a solid titanium material in an inert atmosphere, where the solid titanium material has an initial microstructure with an initial grain size and which is optionally anisotropic. The method can also include introducing hydrogen through a thermal process into the solid titanium material, resulting in a titanium alloy article having a refined microstructure that has a final grain size that is smaller than the initial grain size, or reduced anisotropy, or a combination thereof.
C22F 1/18 - High-melting or refractory metals or alloys based thereon
C22F 1/02 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working in inert or controlled atmosphere or vacuum
54.
COMPOSITIONS AND METHODS FOR TREATING PHOSPHOMANNOMUTASE 2 (PMM2) DEFICIENCY
Disclosed are vectors comprising a nucleic acid sequence capable of encoding Phosphomannomutase 2 (PMM2). Disclosed are vectors comprising a nucleic acid sequence of SEQ ID NO;2. Disclosed are rAAV vectors comprising at least one polynucleotide sequence encoding PMM2. Disclosed are compositions comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of increasing PMM2 expression and/or activity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of glycosylation in cells of a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2. Disclosed are methods of treating a subject having a PMM2 deficiency comprising administering a therapeutically effective amount of a composition comprising a vector comprising a nucleic acid sequence capable of encoding PMM2 to the subject, wherein the composition increases PMM2 expression and/or activity in a cell of the subject.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
55.
POWERED KNEE AND ANKLE PROSTHESIS CONTROLLER FOR ADAPTIVE AMBULATION
Disclosed are embodiments of a volitional controller and prosthetic leg system comprising a volitional controller and a powered prosthetic leg. The volitional controller may be configured to control a powered knee joint and a powered ankle joint to enable a user to walk at different speeds and inclines. The orientation of the components of the powered prosthetic leg may be monitored continuously to enable the system to adapt to changes in the duration of the user's gait. The volitional controller may be configured to determine a target knee torque and a target ankle torque that may be based on the global shank orientation, a prosthetic knee velocity, and a prosthetic ankle velocity.
Disclosed are prosthetic systems comprising a powered knee prosthesis and a volitional controller configured to provide control of the prosthesis to the user. The prosthetic system may be configured to enable a user to walk on smooth and/or uneven terrain and to ascend and/or descend stairs. The volitional controller may be configured in a contact state when the prosthesis is in contact with a ground surface and a no contact state when the prosthesis is lifted from the ground surface. When in the contact state, the controller may output a knee torque signal for controlling the powered knee of the prosthesis. The knee torque signal may be based on a target knee torque determined by the knee orientation and the torque measured at the ankle of a prosthetic foot. When in the no contact state, the controller may output a knee torque signal based on a desired knee position.
An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.
A61M 21/02 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
G02C 7/10 - Filters, e.g. for facilitating adaptation of the eyes to the darkSunglasses
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
Described herein is a cable-actuated head-neck exoskeleton configured to effectively support and provide mobility to the head-neck. The exoskeleton comprises a head brace, a cable mount, a control unit, and a set of cables. Each cable extends from the control unit, through a defined position in the cable mount, and to a defined position in the head brace. The control unit includes a set of actuators. Each actuator of the set of actuators is connected to one of the cables and independently operates to adjust the length of the corresponding cable. Tension in the cables can therefore be independently adjusted to provide controlled tensile forces to the head and thereby generate moments about the cervical joints of the user.
A method ( 100) of producing a neodymium metal can include mixing (1 10) a dissolution agent comprising magnesium with a neodymium-containing feedstock. The dissolution agent and the neodymium-containing feedstock can be heated (120) to an elevated temperature above a melting temperature of the dissolution agent to form a neodymium-magnesium alloy. The neodymium-magnesium alloy can be exposed (130) to hydrogen gas to convert neodymium in the alloy to a. neodymium hydride. The neodymium hydride can be separated (140) from the magnesium in the alloy. The neodymium can be optionally dehydrogenated (150) to yield a purified neodymium product.
B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
H01F 1/04 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials metals or alloys
H01F 1/01 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials
60.
DEVICES INCLUDING FERROELECTRIC NEMATIC MATERIAL AND METHODS OF FORMING AND USING SAME
The Regents of the University of Colorado, a body corporate (USA)
University of Utah Research Foundation (USA)
Inventor
Clark, Noel A.
Chen, Xi
Glaser, Matthew A.
Maclennan, Joseph E.
Dong, Degnpan
Bedrov, Dimitry
Abstract
Devices including nematic liquid crystal-forming molecules are disclosed. The molecules include one or more dipoles and exist in a ferroelectric nematic state. Exemplary devices can further include an electrode for applying an electric field in, for example, and in-plane direction.
G02F 1/141 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on liquid crystals, e.g. single liquid crystal display cells characterised by the electro-optical or magneto-optical effect, e.g. field-induced phase transition, orientation effect, guest-host interaction or dynamic scattering based on orientation effects in which the liquid crystal remains transparent using ferroelectric liquid crystals
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
G02F 1/135 - Liquid crystal cells structurally associated with a photoconducting or a ferro-electric layer, the properties of which can be optically or electrically varied
G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein are polyamide substrates that may be reliably used in additive manufacturing to produce a wide variety of 3D printed articles, protective films or membranes. The polyamide substrate can be formed via thiol-ene click chemistry reactions between diallyl amide or other alkene monomers, reacted with thiol monomers, that can be activated by photoirradiation at relatively low temperatures (e.g., about 80° C.). As a result, the polyamide substrates disclosed herein may be cured using a simple, energy efficient curing process that allows for additive manufacturing where the produced 3d printed article exhibits increased toughness rather than being brittle as are most 3d printed articles.
A trauma gurney includes a base connected to a frame by a vertical adjustment mechanism. The base is configured that it can be maneuvered over a receiving table. The frame holds a detachable platform suitable for the positioning of a patient thereon. Actuation of the adjustment mechanism allows the frame to be lowered and the patient platform to be detached. The patient platform is configured to be non-interfering with various procedures such as MRI procedures so the patient platform can remain with the patient after the patient has been transferred without adverse effects to the procedures. The patient platform can also be reattached to the frame after it has been removed. The trauma gurney beneficially allows a patient to be transferred from the gurney to another surface, such as for imaging, without requiring a conventional lateral transfer. Similarly, the trauma gurney allows a patient to be transferred back to the gurney.
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A bone implant system may include a plurality of bone anchors, a superior rod attachable to a superior portion of a bone via the bone anchors, and an inferior rod attachable to an inferior portion of the bone via the bone anchors. The superior rod may have a superior end, and the inferior rod may have an inferior end. The superior rod may telescopically engage the inferior rod such that a cavity is present within at least one of the superior rod and the inferior rod and such that a length of the combined superior and inferior rods, measured between the superior end and the inferior end, is adjustable. The cavity may contain a micropump and a chamber. The micropump may be configured to expel fluid into the chamber to urge the length to increase.
In one aspect, the invention relates to cyclopeptides and methods of using the disclosed cyclopeptides to treat bacterial infections due to, for example, Gram-negative pathogens. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A parasitic capacitance mitigation circuit for a relaxation oscillator. The parasitic capacitance mitigation circuit includes a first switch coupled across a parasitic capacitance of a resistive sensing element and a second switch coupled between the parasitic capacitance and a reference voltage node. The parasitic capacitance mitigation circuit includes a pulse generator configured to: monitor a voltage across the parasitic capacitance; detect a voltage transient across the parasitic capacitance; and generate a pulse control signal in response to detecting the voltage transient. In response to the pulse control signal, the first switch opens and the second switch closes to discharge the parasitic capacitance through the second switch.
A diffusiophoresis-enhanced particle deposition system can include a deposition surface and a droplet ejector connectable to a supply of particle-containing ink, where the droplet ejector is positioned to eject droplets of the particle-containing ink onto the deposition surface. An atmosphere control chamber can surround the deposition surface. A supply of a solute gas that is soluble in the particle-containing ink can be connected to the atmosphere control chamber to provide a controlled atmospheric concentration of the solute gas to droplets on the deposition surface.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
A bone screw may be insertable into a bone. The bone screw may have a distal member with bone-engaging threads, a proximal member configured to slidably engage the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member.
Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
71.
SYSTEMS AND METHODS FOR FACILITATING RAPID GENOME SEQUENCE ANALYSIS
A method for facilitating rapid genome sequence analysis includes accessing an output stream of an alignment process that includes aligned reads of a biological sequence that are aligned to a reference genome. The method also includes distributing the aligned reads to a plurality of computing nodes based on genomic position. Each of the plurality of computing nodes is assigned to a separate data bin of a plurality of data bins associated with genomic position. The method also includes, for at least one aligned read determined to overlap separate data bins of the plurality of data bins, duplicating the at least one aligned read and distributing the at least one aligned read to separate computing nodes of the plurality of computing nodes that are assigned to the separate data bins.
A microscope imaging system including a microscope having a stage with a well plate having a plurality of therapy treatment samples, an array of light emitting diodes (LEDs) to illuminate the plurality of therapy treatment samples, and a camera to capture images of the plurality of therapy treatment samples over a period of time using the array of LEDs. The microscope imaging system including an electronic controller configured to receive a plurality of images of the plurality of therapy treatment samples over the period of time from the camera, determine a cell mass for each therapy treatment sample based on each image, track the cell mass over the period of time for each therapy treatment sample, determine a plurality of response parameters for each therapy treatment sample based on the tracked cell mass, and determine a treatment response for each therapy treatment sample based on the plurality of response parameters.
Disclosed herein are a polypeptide biosensor and compositions comprising the polypeptide biosensor that detects acetyl coenzyme A (acetyl-CoA). The polypeptide comprises an acetyl-CoA binding protein and a fluorescent protein. Further described herein are methods of using the biosensor to detect acetyl-CoA and expression vectors comprising the biosensor.
Lithium ion batteries and liquid electrolytes for lithium ion batteries are described. An example lithium ion battery can include a cathode, an anode, and a liquid electrolyte in contact with the cathode and the anode. The anode can allow reversible intercalation of lithium ions into the anode. The liquid electrolyte can include a single-oxygen linear ether solvent and a lithium salt at least partially dissolved in the solvent. The lithium salt can include a sulfur-fluorine bond.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF UTAH RESEARCH FOUNDATION (USA)
Inventor
Won, Youngwook
Bull, David A.
Lee, Daniel Yongwon
Abstract
Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Non-aqueous redox flow batteries (NARFB) including a cation (e.g., trimethylammonium ("TMA")) functionalized polyethylene or other polymeric membrane for mitigating electrolyte crossover. Such a battery can exhibit greater than 99%, or even 99.99% average capacity retention per cycle, with at least 50%, or even at least 85% total capacity retention through 1000 charge/discharge cycles. The trimethylammonium (TMA) or other cation functionalized membrane can be formed from copolymerized cycloalkene polymerizable components, e.g., where the copolymerized cycloalkene polymerizable components comprise a trimethylammonium or other quaternary ammonium substituted cycloalkene polymerizable component and a neutral or unsubstituted cycloalkene polymerizable component in a molar ratio of from 1:1 to 1:20, or 1:1 to 1:10, or 1:2 to 1:6.
H01M 8/1023 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having only carbon, e.g. polyarylenes, polystyrenes or polybutadiene-styrenes
H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
H01M 8/20 - Indirect fuel cells, e.g. fuel cells with redox couple being irreversible
77.
CLEAVABLE POLYMER-DRUG CONJUGATES FOR ALZHEIMER'S DISEASE
Described herein are cleavable and non-cleavable polymer-drug conjugates that can cross the blood-brain barrier. An example polymer-drug conjugate includes paclitaxel and a transcytosis peptide that can transport the polymer-drug conjugate across the blood-brain barrier of a subject.. Also described herein are multi-domain conjugates including the polymer-drug conjugate that further include a second cleavable peptide linker. Methods for modulating neurodegenerative conditions with the polymer-drug conjugates and multi-domain conjugates thereof are also described herein.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
C07K 7/04 - Linear peptides containing only normal peptide links
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Disclosed are polypeptides comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises a zinc finger protein 865 (ZNF865) or fragment thereof. Disclosed are polynucleotides capable of encoding a polypeptide comprising two heterologous polypeptide domains, wherein the first polypeptide domain comprises a Cas protein and wherein the second polypeptide domain comprises ZNF865 or fragment thereof. Disclosed are vectors comprising one or more of the polynucleotides. Disclosed are methods of using the disclosed polypeptides, polynucleotides and vectors.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Disclosed herein is a first conjugate comprising a first targeting moiety that is adapted to specifically bind to a first antigen on the surface of a target effector cell and a first morpholino oligonucleotide; and a plurality of additional conjugates comprising a targeting moiety that is adapted to bind to a second antigen that is on the surface of a target B-cell and a morpholino oligonucleotide that is at least 90% complementary to the first morpholino oligonucleotide. Also described herein are kits comprising the conjugates and methods for using the conjugates and kits.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A tether assembly may be attached to a bone to correct a rotational deformity. The bone may have a growth plate that separates a first section of the bone from a second section of the bone. The tether assembly may have a tether member with a first end, a second end, and a central portion extending between the first end and the second end. The first end may have a closed outer wall that defines and fully bounds a first aperture. The second end may have an open outer wall that defines and partially bounds a second aperture. The open outer wall may define a slot in communication with the second aperture. The first and second ends may be securable to the first and second sections of the bone via coupling members inserted through the first and second apertures and anchored in the first and second sections, respectively.
Method and apparatus for detecting and differentiating neurotransmitters using ultraviolet plasmonic-engineered native fluorescence. In one example, the method includes determining a photobleaching rate constant of a neurotransmitter-containing analyte loaded onto a plasmonic-engineered biosensor and subjected to illumination by ultraviolet light. The method further includes submitting a query containing the determined rate constant to a database including calibration data representing a plurality of different neurotransmitters and a plurality of different biosensors. In at least some examples, the queried database returns a response indicating one or more of a predicted identity of the neurotransmitter together with a corresponding confidence score, an estimated amount of the neurotransmitter in the analyte, and an estimated percentage of the neurotransmitter relative to another neurotransmitter in the analyte.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
A trephine may be used to form a tunnel through bone and/or cartilage. The trephine may have a trephine body with a generally tubular shape centered on a trephine body longitudinal axis, and a trephine body distal rim. The trephine may also have a drive shaft that receives torque and transmits the torque to the trephine body. The trephine body distal rim may lie substantially in a plane that is non-perpendicular to the trephine body longitudinal axis. The trephine may further have a cutting tooth extending distally from the trephine body distal rim. The cutting tooth may have a first distal tip and a second distal tip displaced circumferentially from the first distal tip. The trephine may be advanced while rotating to form the tunnel through bone and a first, adjacent cartilage surface of a joint, without breaching a second cartilage surface on the opposite side of the joint.
A segmented image-relay fiber can include concatenating image-relay fiber segments. Each segment can include, or consist of, an optical fiber and an imaging lens. Each segment can accurately reproduce (e.g., with little to no losses or distortion of the image) a light intensity distribution in its input plane at its output plane, while reducing the distortion of the image that occurs in many typical fiber optic image transfers. This approach can be used for a variety of applications, such as micro-endoscopy and communication transmissions that can benefit from spatially preserved information. The recorded images can also be analyzed or processed using various computational methods, including machine learning (e.g., a trained algorithm), to enhance performance.
A bone screw may be insertable into a bone. The bone screw may have a distal member with bone-engaging threads, a proximal member configured to slidably engage the distal member, and a tension member with a proximal end coupled to the proximal member, and a distal end coupled to the distal member such that, in response to motion of the distal member away from the proximal member, the tension member elongates and urges the distal member to move toward the proximal member.
e.ge.ge.g, from about 3:2 to about 4:1), wherein the peptide has a minumum chain length, such as, for example a chain length of at least 30 amino acid residues. The disclosed peptides beneficially inhibit ice crystal formation, and, therefore, offer utility in a wide range of applications, including, but not limited to biomedical cryopreservation, food technology, agriculture, cosmetics, and building materials. Thus, the disclosed peptides can be formulated into a composition (e.g, a cryoprotectant composition, an agricultural formulation, a cosmetic composition) or a food product, or, alternatively, can be attached or coated onto a surface for use in structural applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A method of refining a microstructure of a titanium material can include providing a solid titanium material at a temperature below about 400° C. The titanium material can be heated under a hydrogen-containing atmosphere to a hydrogen charging temperature that is above a β transus temperature of the titanium material and below a melting temperature of the titanium material, and held at this temperature for a time sufficient to convert the titanium material to a substantially homogeneous β phase. The titanium material can be cooled under the hydrogen-containing atmosphere to a phase transformation temperature below the β transus temperature and above about 400° C., and held for a time to produce α phase regions. The titanium material can also be held under a substantially hydrogen-free atmosphere or vacuum at a dehydrogenation temperature below the β transus temperature and above the δ phase decomposition temperature to remove hydrogen from the titanium material.
C22F 1/18 - High-melting or refractory metals or alloys based thereon
C22F 1/02 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working in inert or controlled atmosphere or vacuum
A bone anchor may include a shaft having a distal end and a distal toggle element rotatably coupled to the distal end such that the distal toggle element may be rotatable between: a stowed orientation in which the distal toggle element may be insertable into a bone through an aperture formed in a cortex of the bone; and a deployed orientation in which the distal toggle element may be positioned to abut an interior surface of the cortex around the aperture. The bone anchor may also include a flange having a shoulder that may be moveable distally toward the distal toggle element to abut an exterior surface of the cortex.
Disclosed herein is a degradable polyimide substrate that may be reliably used as an electronic substrate in flexible electronics. The degradable polyimide substrate is formed via thiol-ene click chemistry reactions between diallyl imide or other alkene monomers and thiol monomers, that can be activated by photoirradiation at relatively low temperatures (e.g., about 80° C.). As a result, the degradable polyimide substrates disclosed herein may be cured using a simple, energy efficient curing process that allows for streamlined manufacturing of circuits including multilayered circuits. In some instances, epoxy monomers may be added to the monomer resin used to form the polyimide substrate, wherein selective curing may yield polymer substrates with varying degrees of flexibility and rigidity.
H01L 21/48 - Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the groups or
H01L 21/56 - Encapsulations, e.g. encapsulating layers, coatings
H01L 23/538 - Arrangements for conducting electric current within the device in operation from one component to another the interconnection structure between a plurality of semiconductor chips being formed on, or in, insulating substrates
Provided herein are compositions, systems, and methods for directed evolution. Further provided herein are compositions, systems, and methods comprising use of synthetic promotor libraries for directed evolution.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
90.
UNIQUE MOLECULAR INDEX SEQUENCING FOR GENETIC MUTATIONS
Provided herein are compositions, systems, and methods for directed evolution. Further provided herein are systems and methods comprising use of UMIs with directed evolution.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
A point-of-care diagnostic device configured to measure characteristics of a biological sample. The point-of-care device includes an electronic component package and a complementary metal-oxide-semiconductor (CMOS) biosensor formed on the electronic component package. The CMOS biosensor includes a fluidic system, an electrode array in fluid communication with the fluidic system, and an impedance detection circuit in electrical communication with the electrode detection circuit. The fluidic system is formed on the electronic component package and is configured to transport fluid. The electrode array in fluid communication with the fluidic system and includes a plurality of electrode pairs. The electrode array having a surface coating with an antibody. The impedance detection circuit is in electrical communication with the electrode array and is configured to detect an electrical impedance change caused by a binding of the biological sample to the antibody on each of the electrode pairs.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A bone anchor may include a shaft having a distal end and a distal toggle element rotatably coupled to the distal end such that the distal toggle element may be rotatable between: a stowed orientation in which the distal toggle element may be insertable into a bone through an aperture formed in a cortex of the bone; and a deployed orientation in which the distal toggle element may be positioned to abut an interior surface of the cortex around the aperture. The bone anchor may also include a flange having a shoulder that may be moveable distally toward the distal toggle element to abut an exterior surface of the cortex.
A semi-powered foot and ankle prosthesis (100) has a foot member (128) coupled to the ankle frame (112) and movable with respect to the ankle frame (112). A linear actuator (144) is coupled to and between the ankle frame (112) and the foot member (128) to move the foot member (128) with respect to the ankle frame (112). The linear actuator (144) has a drive motor (150). A locking mechanism (104) selectively engages the drive motor (150) to selectively lock movement of the drive motor (150) to resist a force on the foot member (128) from backdriving the linear actuator (144).
An inerter-based metamaterial for low-frequency vibration attenuation includes a structural matrix material and an inerter array. The inerter array can be embedded within the structural matrix material. The inerter array can include a first inerter cell oriented along a first attenuation axis and a second inerter cell oriented along a second attenuation axis different from the first attenuation axis. The first inerter cell can include a first inerter. The second inerter cell can include a second inerter. The first inerter and the second inerter can be microinerters. The first inerter cell and the second inerter cell can be separated from each other by at least a portion of the matrix material. The first inerter cell and the second inerter cell can each include a first end and a second end and can each be connected to the matrix material at both the first end and the second end.
E02D 31/08 - Protective arrangements for foundations or foundation structuresGround foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution against transmission of vibrations or movements in the foundation soil
96.
METHOD FOR DETECTING ANALYTES WITH METAL-ORGANIC FRAMEWORKS
C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
Described herein are systems and methods for electrochemical absorption/desorption for continuous and selective lithium extraction from aqueous lithium feedstocks. The disclosed systems and methods comprise symmetric electrodes having lithium selective material which absorbs and desorbs lithium ions based on an electric field voltage bias. By continuously cycling the voltage bias between positive and negative electric potentials, the absorption and desorption of lithium ions can be selectively controlled to allow efficient lithium extraction.
A base station associated with user devices in a wireless network includes a plurality of base stations. The base station includes a processor and a memory including instructions that, when executed by the processor, cause the base station to function as an actor network configured to determine a current transmit power, a critic network configured to evaluate a quality function of previous transmit powers of the base station based on local observations and previous transmit powers of neighboring base stations, and a decentralized training unit configured to train the quality function over the neighboring base stations. The neighboring base stations are a subset of the plurality of base stations, and the current transmit power is determined based on the previous transmit powers of the base station, direct channel gains between the base station and the user devices, and interference measures from the user devices.
Provided are recombinant adeno-associated virus (r.AAV) vectors comprising a transgene to express galactose-1-phosphate uridylyl transferase (GALT); virions comprising said vectors (r.AAV virions); methods of their production; methods of their use, including methods for treating galactosemia, GALT-deficiency, symptoms therefrom: and kits. These recombinant adeno-associated virus (rAAV) vectors comprise a method of treating galactosemia in a subject in need.
